A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
Ditching Invading DNA: Bacteria and archaea protect themselves from invasive foreign nucleic acids through an RNA-mediated adaptive immune system called CRISPR (clustered regularly interspaced short palindromic repeats)/CRISPR-associated (Cas). Jinek et al. (p. 816 , published online 28 June; see the Perspective by Brouns ) found that for the type II CRISPR/Cas system, the CRISPR RNA (crRNA) as well as the trans-activating crRNA—which is known to be involved in the pre-crRNA processing—were both required to direct the Cas9 endonuclease to cleave the invading target DNA. Furthermore, engineered RNA molecules were able to program the Cas9 endonuclease to cleave specific DNA sequences to generate double-stranded DNA breaks.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Repurposing bacterial “CRISPR” systems to facilitate RNA-guided cleavage of complementary DNA has revolutionized the field of gene editing in mammalian cells 1–4.”
From A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells (2018) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“To realize this promise, the development of CRISPR-Cas9 for genome editing offers a simpler technology that has been adopted widely due to the ease of programming its DNA binding and modifying capabilities.”
From The promise and challenge of therapeutic genome editing (2020) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recombinant expression and purification of EvoCas9–1 paired with chemically synthesized Evo-generated single guide RNA (sgRNA) exhibited comparable in vitro cleavage activity to SpCas9 paired with the canonical SpCas9 sgRNA”
From Sequence modeling and design from molecular to genome scale with Evo (2024) · cites this paper as [62]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Cas9 can create DNA cleavage at desired genomic positions that are guided by precise base pairing between sgRNA and DNA, adjacent to a protospacer-adjacent motif (PAM) (Jinek et al., 2012; Cho et al., 2013; Cong et al., 2013; Wang et al., 2016a).”
From Off-target effects in CRISPR/Cas9 gene editing (2023) · cites this paper as Jinek et al., 2012
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“CRISPR/Cas9 is a class of ribonucleoprotein complexes formed by a Cas9 protein and a single guide RNA (sgRNA) (Jinek et al., 2012; Cho et al., 2013; Cong et al., 2013; Wang et al., 2016a).”
From Off-target effects in CRISPR/Cas9 gene editing (2023) · cites this paper as Jinek et al., 2012
Experimental — accuracy not yet measured
31 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular Cloning: A Laboratory Manual
Sambrook, J., Fritsch, E., & Maniatis, T. (1989) · UCLA - Biblioteca de Ciencias de la Salud · Cited by 133,589
Lewis, B. P., Burge, C. B., & Bartel, D. P. (2005) · Cell · doi:10.1016/j.cell.2004.12.035 · Cited by 11,855
CRISPR Provides Acquired Resistance Against Viruses in Prokaryotes
Barrangou, R., Fremaux, C., Deveau, H., Richards, M., Boyaval, P., Moineau, S., Romero, D. A., & Horvath, P. (2007) · Science · doi:10.1126/science.1138140 · Cited by 5,947
CRISPR RNA Maturation by Trans-Encoded Small RNA and Host Factor RNase III
Deltcheva, E., Chylinski, K., Sharma, C. M., Gonzales, K., Chao, Y., Pirzada, Z. A., Eckert, M. R., Vogel, J., & Charpentier, E. (2011) · Nature · doi:10.1038/nature09886 · Cited by 2,563
Self-citationSmall CRISPR RNAs Guide Antiviral Defense in Prokaryotes
Brouns, S. J. J., Jore, M. M., Lundgren, M., Westra, E. R., Slijkhuis, R. J. H., Snijders, A. P. L., Dickman, M. J., Makarova, K. S., Koonin, E. V., & van der Oost, J. (2008) · Science · doi:10.1126/science.1159689 · Cited by 2,460
Evolution and classification of the CRISPR–Cas systems
Makarova, K. S., Haft, D. H., Barrangou, R., Brouns, S. J. J., Charpentier, E., Horvath, P., Moineau, S., Mojica, F. J. M., Wolf, Y. I., Yakunin, A. F., et al. (2011) · Nature Reviews Microbiology · doi:10.1038/nrmicro2577 · Cited by 2,331
Self-citationThe CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA
Garneau, J. E., Dupuis, M.-È., Villion, M., Romero, D. A., Barrangou, R., Boyaval, P., Fremaux, C., Horvath, P., Magadán, A. H., & Moineau, S. (2010) · Nature · doi:10.1038/nature09523 · Cited by 2,328
Genome editing with engineered zinc finger nucleases
Urnov, F. D., Rebar, E. J., Holmes, M. C., Zhang, H. S., & Gregory, P. D. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2842 · Cited by 2,285
A TALE nuclease architecture for efficient genome editing
Miller, J. C., Tan, S., Qiao, G., Barlow, K. A., Wang, J., Xia, D. F., Meng, X., Paschon, D. E., Leung, E., Hinkley, S. J., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1755 · Cited by 2,098
Targeting DNA Double-Strand Breaks with TAL Effector Nucleases
Christian, M., Cermak, T., Doyle, E. L., Schmidt, C., Zhang, F., Hummel, A., Bogdanove, A. J., & Voytas, D. F. (2010) · Genetics · doi:10.1534/genetics.110.120717 · Cited by 1,869
Cited by
Items 301–400 of 1,285
Directed evolution of adenine base editors with increased activity and therapeutic application
Gaudelli, N. M., Lam, D. K., Rees, H. A., Solá-Esteves, N. M., Barrera, L. A., Born, D. A., Edwards, A., Gehrke, J. M., Lee, S.-J., Liquori, A. J., et al. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0491-6 · Cited by 524
Alsaiari, S. K., Patil, S., Alyami, M., Alamoudi, K. O., Aleisa, F. A., Merzaban, J. S., Li, M., & Khashab, N. M. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.7b11754 · Cited by 517
CRISPR/Cpf1-mediated DNA-free plant genome editing
Kim, H., Kim, S.-T., Ryu, J., Kang, B.-C., Kim, J.-S., & Kim, S.-G. (2017) · Nature Communications · doi:10.1038/ncomms14406 · Cited by 514
Choosing the Right Tool for the Job: RNAi, TALEN, or CRISPR
Boettcher, M., & McManus, M. T. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.04.028 · Cited by 516
High-throughput gene targeting and phenotyping in zebrafish using CRISPR/Cas9
Varshney, G. K., Pei, W., LaFave, M. C., Idol, J., Xu, L., Gallardo, V., Carrington, B., Bishop, K., Jones, M., Li, M., et al. (2015) · Genome Research · doi:10.1101/gr.186379.114 · Cited by 509
“…palindromic repeats (CRISPR)/CRISPR-associated (Cas) system has emerged as a new, targetedmutagenesismethod inmany species, including zebrafish (Gasiunas et al. 2012; Jinek et al. 2012; Cong et al. 2013; Hwang et al. 2013a,b; Jao et al. 2013; Mali et al. 2013; Gagnon et al. 2014; Hsu et al. 2014).”
BackgroundAdvances in fluorescence labeling strategies for dynamic cellular imaging
Dean, K. M., & Palmer, A. E. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1556 · Cited by 512
Functionally diverse type V CRISPR-Cas systems
Yan, W. X., Hunnewell, P., Alfonse, L. E., Carte, J. M., Keston-Smith, E., Sothiselvam, S., Garrity, A. J., Chong, S., Makarova, K. S., Koonin, E. V., et al. (2019) · Science · doi:10.1126/science.aav7271 · Cited by 518
Defining and improving the genome-wide specificities of CRISPR–Cas9 nucleases
Tsai, S. Q., & Joung, J. K. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2016.28 · Cited by 510
Comparison of Cas9 activators in multiple species
Chavez, A., Tuttle, M., Pruitt, B. W., Ewen-Campen, B., Chari, R., Ter-Ovanesyan, D., Haque, S. J., Cecchi, R. J., Kowal, E. J. K., Buchthal, J., et al. (2016) · Nature Methods · doi:10.1038/nmeth.3871 · Cited by 519
“This process requires complementarity between the Cas9-associated guide RNA (gRNA) and the target site, along with the presence of a short protospacer adjacent motif 3,4,5,6 .”
CRISPR/Cas9-mediated viral interference in plants
Ali, Z., Abulfaraj, A., Idris, A., Ali, S., Tashkandi, M., & Mahfouz, M. M. (2015) · Genome Biology · doi:10.1186/s13059-015-0799-6 · Cited by 500
The Molecular Architecture for RNA-Guided RNA Cleavage by Cas13a
Liu, L., Li, X., Ma, J., Li, Z., You, L., Wang, J., Wang, M., Zhang, X., & Wang, Y. (2017) · Cell · doi:10.1016/j.cell.2017.06.050 · Cited by 538
“…in contrast to type II Cas9 and type V Cas12a and Cas12b proteins, the type I Cascade complex, and the type III CRISPR-effector complex, which cleave target DNA or RNA at specific sites (Jinek et al., 2012; Shmakov et al., 2015; Zetsche et al., 2015; Hale et al., 2009;Mulepati and Bailey, 2013).”
Rescue of Fragile X Syndrome Neurons by DNA Methylation Editing of the FMR1 Gene
Liu, X. S., Wu, H., Krzisch, M., Wu, X., Graef, J., Muffat, J., Hnisz, D., Li, C. H., Yuan, B., Xu, C., et al. (2018) · Cell · doi:10.1016/j.cell.2018.01.012 · Cited by 512
Augmentation of Antitumor Immunity by Human and Mouse CAR T Cells Secreting IL-18
Hu, B., Ren, J., Luo, Y., Keith, B., Young, R. M., Scholler, J., Zhao, Y., & June, C. H. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.09.002 · Cited by 506
Ding, Q., Regan, S. N., Xia, Y., Oostrom, L. A., Cowan, C. A., & Musunuru, K. (2013) · Cell Stem Cell · doi:10.1016/j.stem.2013.03.006 · Cited by 459
Nanoparticle-Mediated Delivery towards Advancing Plant Genetic Engineering
Cunningham, F. J., Goh, N. S., Demirer, G. S., Matos, J. L., & Landry, M. P. (2018) · Trends in Biotechnology · doi:10.1016/j.tibtech.2018.03.009 · Cited by 496
mRNA-based cancer therapeutics
Liu, C., Shi, Q., Huang, X., Koo, S., Kong, N., & Tao, W. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-023-00586-2 · Cited by 500
Induced Pluripotent Stem Cells Meet Genome Editing
Hockemeyer, D., & Jaenisch, R. (2016) · Cell Stem Cell · doi:10.1016/j.stem.2016.04.013 · Cited by 499
“In 2012 the collaborative work of the Jennifer Doudna and Emmanuelle Charpentier laboratories demonstrated that in CRISPR type-2 systems a single protein, Cas9, can function as a designer SSN, by associating with an engineered single guide RNA (sgRNA) that bears homology to a genetic locus of interest (Jinek et al., 2…”
BackgroundInfluentialStructure-guided chemical modification of guide RNA enables potent non-viral in vivo genome editing
Yin, H., Song, C.-Q., Suresh, S., Wu, Q., Walsh, S., Rhym, L. H., Mintzer, E., Bolukbasi, M. F., Zhu, L. J., Kauffman, K., et al. (2017) · Nature Biotechnology · doi:10.1038/nbt.4005 · Cited by 499
“plasmid expressing sgRNAs from a U6 promoter, (2) unmodified sgRNA, (3) 5′&3′-sgRNA or (4) e-sgRNA.”
BackgroundMethodExpanded base editing in rice and wheat using a Cas9-adenosine deaminase fusion
Li, C., Zong, Y., Wang, Y., Jin, S., Zhang, D., Song, Q., Zhang, R., & Gao, C. (2018) · Genome Biology · doi:10.1186/s13059-018-1443-z · Cited by 497
“CRISPR/Cas9 and CRISPR/Cpf1 typically produce double strand breaks (DSBs) that result in mutant plants with either gene knock-outs (via non-homologous end joining (NHEJ)) or gene replacements and insertions (via homology-directed repair (HDR)) [2, 3].”
BackgroundClassification and evolution of type II CRISPR-Cas systems
Chylinski, K., Makarova, K. S., Charpentier, E., & Koonin, E. V. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku241 · Cited by 498
“The diversity of tracrRNA length and nucleotide sequences upstream and downstream of the anti-repeats (22,23), together with the functionality of substantially truncated tracrRNA-derived parts of single guide RNAs that have been used for genome editing, suggest that the tracrRNA sequences outside the functional anti-r…”
BackgroundInfluentialSelf-citationLi, M., Li, X., Zhou, Z., Wu, P., Fang, M., Pan, X., Lin, Q., Luo, W., Wu, G., & Li, H. (2016) · Frontiers in Plant Science · doi:10.3389/fpls.2016.00377 · Cited by 496
Targeted DNA demethylation in vivo using dCas9–peptide repeat and scFv–TET1 catalytic domain fusions
Morita, S., Noguchi, H., Horii, T., Nakabayashi, K., Kimura, M., Okamura, K., Sakai, A., Nakashima, H., Hata, K., Nakashima, K., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3658 · Cited by 502
Lander, E. S. (2016) · Cell · doi:10.1016/j.cell.2015.12.041 · Cited by 488
“They used recombinant Cas9 (from S. pyogenes expressed in E. coli) and crRNA and tracrRNA that had been transcribed in vitro (Jinek et al., 2012).”
BackgroundMethodJia, H., Zhang, Y., Orbović, V., Xu, J., White, F. F., Jones, J. B., & Wang, N. (2017) · Plant Biotechnology Journal · doi:10.1111/pbi.12677 · Cited by 486
Origins and evolution of CRISPR-Cas systems
Koonin, E. V., & Makarova, K. S. (2019) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2018.0087 · Cited by 494
González, F., Zhu, Z., Shi, Z.-D., Lelli, K., Verma, N., Li, Q. V., & Huangfu, D. (2014) · Cell Stem Cell · doi:10.1016/j.stem.2014.05.018 · Cited by 503
“The type II CRISPR/Cas system requires two components: the DNA endonuclease Cas9 protein for DNA cleavage and a variable CRISPR RNA (crRNA) and trans-activating crRNA (tracrRNA) duplex for DNA target recognition (Jinek et al., 2012).”
MethodHan, K., Jeng, E. E., Hess, G. T., Morgens, D. W., Li, A., & Bassik, M. C. (2017) · Nature Biotechnology · doi:10.1038/nbt.3834 · Cited by 498
“Creation of such maps using the CRISPR-Cas9 system, which allows for precise gene disruption with minimal off-target effects 18–20 , would be a transformative tool for dissection of genetic interaction networks.”
CRISPR-Cas9 DNA Base-Editing and Prime-Editing
Kantor, A., McClements, M., & MacLaren, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176240 · Cited by 462
“If the DNA sequence matches the sgRNA target sequence, the HNH and RuvC catalytic domains of the endonuclease cleave both strands of the target DNA, generating a double strand break [18].”
BackgroundCheating evolution: engineering gene drives to manipulate the fate of wild populations
Champer, J., Buchman, A., & Akbari, O. S. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2015.34 · Cited by 496
Mapping the genomic landscape of CRISPR-Cas9 cleavage
Cameron, P., Fuller, C. K., Donohoue, P. D., Jones, B. N., Thompson, M. S., Carter, M. M., Gradia, S., Vidal, B., Garner, E., Slorach, E. M., et al. (2017) · Nature Methods · doi:10.1038/nmeth.4284 · Cited by 443
“For some guides ( FANCF and PTPRC target 2), specificity at the 3 ′ end of the protospacer was preserved at all concentrations, consistent with the ‘seed sequence’ model of Cas9 guide RNA specificity 4 ; whereas for other guides (i.e., CD34 , PAPSS2 ) this trend was less clear.”
ResultA field of dreams: Lignin valorization into chemicals, materials, fuels, and health-care products
Becker, J., & Wittmann, C. (2019) · Biotechnology Advances · doi:10.1016/j.biotechadv.2019.02.016 · Cited by 483
Kim, S. M., Yang, Y., Oh, S. J., Hong, Y., Seo, M., & Jang, M. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.09.013 · Cited by 481
CRISPR/Cas9 Platforms for Genome Editing in Plants: Developments and Applications
Ma, X., Zhu, Q., Chen, Y., & Liu, Y.-G. (2016) · Molecular Plant · doi:10.1016/j.molp.2016.04.009 · Cited by 479
Organoids: Modeling Development and the Stem Cell Niche in a Dish
Kretzschmar, K., & Clevers, H. (2016) · Developmental Cell · doi:10.1016/j.devcel.2016.08.014 · Cited by 479
“…tools, such as clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated proteins (Cas9) technology (Cong et al., 2013; Jinek et al., 2012, 2013; Yang et al., 2013) and the analysis of gene expression on a single-cell level (Grün et al., 2015, 2016) as well as in the…”
MethodMetabolic engineering of Escherichia coli using CRISPR–Cas9 meditated genome editing
Li, Y., Lin, Z., Huang, C., Zhang, Y., Wang, Z., Tang, Y.-J., Chen, T., & Zhao, X. (2015) · Metabolic Engineering · doi:10.1016/j.ymben.2015.06.006 · Cited by 484
Current applications and future perspective of CRISPR/Cas9 gene editing in cancer
Wang, S.-W., Gao, C., Zheng, Y.-M., Yi, L., Lu, J.-C., Huang, X.-Y., Cai, J.-B., Zhang, P.-F., Cui, Y.-H., & Ke, A.-W. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01518-8 · Cited by 478
“In addition, the tracrRNA: crRNA structure can be a single guide RNA (sgRNA), which simplifies components of the CRISPR system and allows Cas9 to target any DNA sequence by changing the sgRNA sequence [13] as long as it is adjacent to the protospacer adjacent motif (PAM).”
BackgroundMechanism and Applications of CRISPR/Cas-9-Mediated Genome Editing
Mengstie, M. A., & Wondimu, B. Z. (2021) · Biologics: Targets and Therapy · doi:10.2147/btt.s326422 · Cited by 478
DeWitt, M. A., Magis, W., Bray, N. L., Wang, T., Berman, J. R., Urbinati, F., Heo, S.-J., Mitros, T., Muñoz, D. P., Boffelli, D., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf9336 · Cited by 477
“Guided by a single guide RNA(sgRNA), theCas9nuclease canbe programmed to cut a target locus within the genome, allowing rapid iteration and optimization not possible with other gene editing approaches (23, 25).”
MethodEfficient ablation of genes in human hematopoietic stem and effector cells using CRISPR/Cas9
Mandal, P. K., Ferreira, L. M. R., Collins, R., Meissner, T. B., Boutwell, C. L., Friesen, M., Vrbanac, V., Garrison, B. S., Stortchevoi, A., Bryder, D., et al. (2014) · Cell stem cell · doi:10.1016/j.stem.2014.10.004 · Cited by 475
“The recent emergence of the clustered, regularly interspaced, palindromic repeats (CRISPR) system for gene editing has the potential to overcome these limitations (Jinek et al., 2012).”
Base editing: advances and therapeutic opportunities
Porto, E. M., Komor, A. C., Slaymaker, I. M., & Yeo, G. W. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0084-6 · Cited by 476
CRISPR-Cas9 genome editing induces megabase-scale chromosomal truncations
Cullot, G., Boutin, J., Toutain, J., Prat, F., Pennamen, P., Rooryck, C., Teichmann, M., Rousseau, E., Lamrissi-Garcia, I., Guyonnet-Duperat, V., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09006-2 · Cited by 474
Veres, A., Gosis, B. S., Ding, Q., Collins, R., Ragavendran, A., Brand, H., Erdin, S., Cowan, C. A., Talkowski, M. E., & Musunuru, K. (2014) · Cell Stem Cell · doi:10.1016/j.stem.2014.04.020 · Cited by 474
“The most commonly employed CRISPR-Cas system, derived from Streptococcus pyogenes, uses Cas9 nuclease that complexes with a guide RNA that hybridizes a 20-nucleotide DNA sequence (protospacer) immediately preceding an NGG motif (protospacer-associated motif, or PAM), resulting in a double-strand break (DSB) three base…”
InfluentialZhang, J.-P., Li, X.-L., Li, G.-H., Chen, W., Arakaki, C., Botimer, G. D., Baylink, D., Zhang, L., Wen, W., Fu, Y.-W., et al. (2017) · Genome Biology · doi:10.1186/s13059-017-1164-8 · Cited by 478
An enhanced CRISPR repressor for targeted mammalian gene regulation
Yeo, N. C., Chavez, A., Lance-Byrne, A., Chan, Y., Menn, D., Milanova, D., Kuo, C.-C., Guo, X., Sharma, S., Tung, A., et al. (2018) · Nature Methods · doi:10.1038/s41592-018-0048-5 · Cited by 496
Chromatin connectivity maps reveal dynamic promoter–enhancer long-range associations
Zhang, Y., Wong, C.-H., Birnbaum, R. Y., Li, G., Favaro, R., Ngan, C. Y., Lim, J., Tai, E., Poh, H. M., Wong, E., et al. (2013) · Nature · doi:10.1038/nature12716 · Cited by 478
Synthetic lethality as an engine for cancer drug target discovery
Huang, A., Garraway, L. A., Ashworth, A., & Weber, B. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0046-z · Cited by 469
Directed evolution using dCas9-targeted somatic hypermutation in mammalian cells
Hess, G. T., Frésard, L., Han, K., Lee, C. H., Li, A., Cimprich, K. A., Montgomery, S. B., & Bassik, M. C. (2016) · Nature Methods · doi:10.1038/nmeth.4038 · Cited by 476
Sun, Y., Jiao, G., Liu, Z., Zhang, X., Li, J., Guo, X., Du, W., Du, J., Francis, F., Zhao, Y., et al. (2017) · Frontiers in Plant Science · doi:10.3389/fpls.2017.00298 · Cited by 467
Efficient CRISPR/Cas9 genome editing with low off-target effects in zebrafish
Hruscha, A., Krawitz, P., Rechenberg, A., Heinrich, V., Hecht, J., Haass, C., & Schmid, B. (2013) · Development · doi:10.1242/dev.099085 · Cited by 478
“described to be crucial for binding) (Cong et al., 2013; Jinek et al., 2012) Fig.”
BackgroundMethodInfluentialPrecision genome engineering and agriculture: opportunities and regulatory challenges
Voytas, D. F., & Gao, C. (2014) · PLoS Biology · doi:10.1371/journal.pbio.1001877 · Cited by 458
“With CRISPR/Cas9, targeting is achieved through a guide RNA that base pairs with a specific chromosomal target sequence (Figure 1D) [12,13].”
BackgroundCas1–Cas2 complex formation mediates spacer acquisition during CRISPR–Cas adaptive immunity
Nuñez, J. K., Kranzusch, P. J., Noeske, J., Wright, A. V., Davies, C. W., & Doudna, J. A. (2014) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2820 · Cited by 458
Self-citationGlycosylase base editors enable C-to-A and C-to-G base changes
Zhao, D., Li, J., Li, S., Xin, X., Hu, M., Price, M. A., Rosser, S. J., Bi, C., & Zhang, X. (2021) · Nature Biotechnology · doi:10.1038/s41587-020-0592-2 · Cited by 460
Latest Developed Strategies to Minimize the Off-Target Effects in CRISPR-Cas-Mediated Genome Editing
Naeem, M., Majeed, S., Hoque, M. Z., & Ahmad, I. (2020) · Cells · doi:10.3390/cells9071608 · Cited by 457
Yan, W. X., Chong, S., Zhang, H., Makarova, K. S., Koonin, E. V., Cheng, D. R., & Scott, D. A. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.02.028 · Cited by 462
“The relative simplicity of the organization of class 2 systems has enabled their widespread adoption as a toolkit for genome editing and other applications (Cong et al., 2013; Gasiunas et al., 2012; Hsu et al., 2014; Jinek et al., 2012; Mali et al., 2013; Wright et al., 2016).”
BackgroundSmall molecules enhance CRISPR genome editing in pluripotent stem cells
Yu, C., Liu, Y., Ma, T., Liu, K., Xu, S., Zhang, Y., Liu, H., La Russa, M., Xie, M., Ding, S., et al. (2015) · Cell stem cell · doi:10.1016/j.stem.2015.01.003 · Cited by 455
“The CRISPR system derived from Streptococcus pyogenes uses a Cas9 nuclease protein that complexes with a single guide RNA (sgRNA) containing a 20-nucleotide (nt) sequence for introducing site-specific double-stranded breaks (Hsu et al., 2013; Jinek et al., 2012).”
The present and future of the Cancer Dependency Map
Arafeh, R., Shibue, T., Dempster, J. M., Hahn, W. C., & Vazquez, F. (2025) · Nature Reviews Cancer · doi:10.1038/s41568-024-00763-x · Cited by 454
Inhibition of CRISPR-Cas9 with Bacteriophage Proteins
Rauch, B. J., Silvis, M. R., Hultquist, J. F., Waters, C. S., McGregor, M. J., Krogan, N. J., & Bondy-Denomy, J. (2017) · Cell · doi:10.1016/j.cell.2016.12.009 · Cited by 460
“Most technologies are based on Cas9 (class 2, type II-A) from Streptococcus pyogenes (Spy), together with an engineered single guide RNA (sgRNA) because of the simplicity of the system (Jinek et al., 2012).”
DNA Repair Profiling Reveals Nonrandom Outcomes at Cas9-Mediated Breaks
van Overbeek, M., Capurso, D., Carter, M. M., Thompson, M. S., Frias, E., Russ, C., Reece-Hoyes, J. S., Nye, C., Gradia, S., Vidal, B., et al. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.06.037 · Cited by 454
Efficient Gene Disruption in Diverse Strains of Toxoplasma gondii Using CRISPR/CAS9
Shen, B., Brown, K. M., Lee, T. D., & Sibley, L. D. (2014) · mBio · doi:10.1128/mbio.01114-14 · Cited by 473
In vivo target gene activation via CRISPR/Cas9-mediated trans-epigenetic modulation
Liao, H.-K., Hatanaka, F., Araoka, T., Reddy, P., Wu, M.-Z., Sui, Y., Yamauchi, T., Sakurai, M., O’Keefe, D. D., Núñez-Delicado, E., et al. (2017) · Cell · doi:10.1016/j.cell.2017.10.025 · Cited by 451
“In particular, discovery of the bacterial immune system, CRISPR/Cas9, has led to the development of tools for rapid and efficient RNA-based, sequence-specific genome editing (Jinek et al., 2012).”
Editing the epigenome: technologies for programmable transcription and epigenetic modulation
Thakore, P. I., Black, J. B., Hilton, I. B., & Gersbach, C. A. (2016) · Nature Methods · doi:10.1038/nmeth.3733 · Cited by 451
Applications and potential of genome editing in crop improvement
Zhang, Y., Massel, K., Godwin, I. D., & Gao, C. (2018) · Genome Biology · doi:10.1186/s13059-018-1586-y · Cited by 437
“regularly interspaced short palindromic repeats (CRISPR)/ Cas systems [8] which provide simplicity and ease of tarIntroduction”
BackgroundEngineering the next generation of cell-based therapeutics
Bashor, C. J., Hilton, I. B., Bandukwala, H., Smith, D. M., & Veiseh, O. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00476-6 · Cited by 439
Klann, T. S., Black, J. B., Chellappan, M., Safi, A., Song, L., Hilton, I. B., Crawford, G. E., Reddy, T. E., & Gersbach, C. A. (2017) · Nature Biotechnology · doi:10.1038/nbt.3853 · Cited by 447
Genetic Dissection of Neural Circuits: A Decade of Progress
Luo, L., Callaway, E. M., & Svoboda, K. (2018) · Neuron · doi:10.1016/j.neuron.2018.03.040 · Cited by 448
Direct observation of R-loop formation by single RNA-guided Cas9 and Cascade effector complexes
Szczelkun, M. D., Tikhomirova, M. S., Sinkunas, T., Gasiunas, G., Karvelis, T., Pschera, P., Siksnys, V., & Seidel, R. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1402597111 · Cited by 453
CRISPR-Cas: biology, mechanisms and relevance
Hille, F., & Charpentier, E. (2016) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2015.0496 · Cited by 442
Self-citationCornerstones of CRISPR–Cas in drug discovery and therapy
Fellmann, C., Gowen, B. G., Lin, P.-C., Doudna, J. A., & Corn, J. E. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.238 · Cited by 443
Self-citationA CRISPR/Cas system mediates bacterial innate immune evasion and virulence
Sampson, T. R., Saroj, S. D., Llewellyn, A. C., Tzeng, Y.-L., & Weiss, D. S. (2013) · Nature · doi:10.1038/nature12048 · Cited by 443
Annotation and Classification of CRISPR-Cas Systems
Makarova, K. S., & Koonin, E. V. (2015) · Methods in Molecular Biology · doi:10.1007/978-1-4939-2687-9_4 · Cited by 437
Synthetic recording and in situ readout of lineage information in single cells
Frieda, K. L., Linton, J. M., Hormoz, S., Choi, J., Chow, K.-H. K., Singer, Z. S., Budde, M. W., Elowitz, M. B., & Cai, L. (2017) · Nature · doi:10.1038/nature20777 · Cited by 440
Current understanding of osteoarthritis pathogenesis and relevant new approaches
Tong, L., Yu, H., Huang, X., Shen, J., Xiao, G., Chen, L., Wang, H., Xing, L., & Chen, D. (2022) · Bone Research · doi:10.1038/s41413-022-00226-9 · Cited by 437
Programmable Removal of Bacterial Strains by Use of Genome-Targeting CRISPR-Cas Systems
Gomaa, A. A., Klumpe, H. E., Luo, M. L., Selle, K., Barrangou, R., & Beisel, C. L. (2014) · mBio · doi:10.1128/mbio.00928-13 · Cited by 433
“The array could even be reduced to a single repeat-spacer, paralleling the engineering of single-guide RNAs for use with Cas9 (32).”
BackgroundCRISPR-Cas12a: Functional overview and applications
Paul, B., & Montoya, G. (2020) · Biomedical Journal · doi:10.1016/j.bj.2019.10.005 · Cited by 409
Genome editing in potato via CRISPR‐Cas9 ribonucleoprotein delivery
Andersson, M., Turesson, H., Olsson, N., Fält, A., Ohlsson, P., Gonzalez, M. N., Samuelsson, M., & Hofvander, P. (2018) · Physiologia Plantarum · doi:10.1111/ppl.12731 · Cited by 432
Unbiased detection of CRISPR off-targets in vivo using DISCOVER-Seq
Wienert, B., Wyman, S. K., Richardson, C. D., Yeh, C. D., Akcakaya, P., Porritt, M. J., Morlock, M., Vu, J. T., Kazane, K. R., Watry, H. L., et al. (2019) · Science · doi:10.1126/science.aav9023 · Cited by 434
“8 While SpCas9 makes relatively blunt-ended cuts (31), other nucleases such as Cas12a (also known 151 as Cpf1) produce staggered DSBs with a four nucleotide 5’-overhang (35).”
BackgroundResultDNA Repair Pathway Choices in CRISPR-Cas9-Mediated Genome Editing
Xue, C., & Greene, E. C. (2021) · Trends in Genetics · doi:10.1016/j.tig.2021.02.008 · Cited by 431
Gene replacements and insertions in rice by intron targeting using CRISPR–Cas9
Li, J., Meng, X., Zong, Y., Chen, K., Zhang, H., Liu, J., Li, J., & Gao, C. (2016) · Nature Plants · doi:10.1038/nplants.2016.139 · Cited by 428
CRISPR-Cas9 Based Engineering of Actinomycetal Genomes
Tong, Y., Charusanti, P., Zhang, L., Weber, T., & Lee, S. Y. (2015) · ACS Synthetic Biology · doi:10.1021/acssynbio.5b00038 · Cited by 432
Strategies in the delivery of Cas9 ribonucleoprotein for CRISPR/Cas9 genome editing
Zhang, S., Shen, J., Li, D., & Cheng, Y. (2021) · Theranostics · doi:10.7150/thno.47007 · Cited by 430
Crystal Structure of Staphylococcus aureus Cas9
Nishimasu, H., Cong, L., Yan, W. X., Ran, F. A., Zetsche, B., Li, Y., Kurabayashi, A., Ishitani, R., Zhang, F., & Nureki, O. (2015) · Cell · doi:10.1016/j.cell.2015.08.007 · Cited by 433
Nissim, L., Perli, S. D., Fridkin, A., Perez-Pinera, P., & Lu, T. K. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.04.022 · Cited by 438
“Cas9’s nuclease activity has been adapted for precise and efficient genome editing in prokaryotic and eukaryotic cells (Cong et al., 2013; Jiang et al., 2013; Jinek et al., 2012; Jinek et al., 2013; Mali et al., 2013b).”
Comparative genomics of defense systems in archaea and bacteria
Makarova, K. S., Wolf, Y. I., & Koonin, E. V. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt157 · Cited by 435
“During this process, the HNH nuclease domain of Cas9 cleaves the strand of the target DNA that is complementary to the crRNA, whereas the RuvC domain cleaves the second strand (95).”
BackgroundMashiko, D., Fujihara, Y., Satouh, Y., Miyata, H., Isotani, A., & Ikawa, M. (2013) · Scientific Reports · doi:10.1038/srep03355 · Cited by 428
Xu, Y., & Li, Z. (2020) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2020.08.031 · Cited by 404
Li, W., Teng, F., Li, T., & Zhou, Q. (2013) · Nature Biotechnology · doi:10.1038/nbt.2652 · Cited by 425
Rees, H. A., Komor, A. C., Yeh, W.-H., Caetano-Lopes, J., Warman, M., Edge, A. S. B., & Liu, D. R. (2017) · Nature Communications · doi:10.1038/ncomms15790 · Cited by 412
CRISPR/Cas9-induced knockout and knock-in mutations in Chlamydomonas reinhardtii
Shin, S.-E., Lim, J.-M., Koh, H. G., Kim, E. K., Kang, N. K., Jeon, S., Kwon, S., Shin, W.-S., Lee, B., Hwangbo, K., et al. (2016) · Scientific Reports · doi:10.1038/srep27810 · Cited by 423
Zhu, S., Li, W., Liu, J., Chen, C.-H., Liao, Q., Xu, P., Xu, H., Xiao, T., Cao, Z., Peng, J., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3715 · Cited by 425
“For each lncRNA or gene, if there are not enough pgRNAs, we also included pgRNAs that (1) do not cross over TSS or (2) have different orientation compared with targeted lncRNA or gene.”
BackgroundDias, M. F., Joo, K., Kemp, J. A., Fialho, S. L., da Silva Cunha, A., Woo, S. J., & Kwon, Y. J. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2017.10.004 · Cited by 413
Point-of-care CRISPR/Cas nucleic acid detection: Recent advances, challenges and opportunities
van Dongen, J. E., Berendsen, J. T. W., Steenbergen, R. D. M., Wolthuis, R. M. F., Eijkel, J. C. T., & Segerink, L. I. (2020) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2020.112445 · Cited by 416
Small molecule–triggered Cas9 protein with improved genome-editing specificity
Davis, K. M., Pattanayak, V., Thompson, D. B., Zuris, J. A., & Liu, D. R. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1793 · Cited by 418
Engineering of CRISPR/Cas9‐mediated potyvirus resistance in transgene‐free Arabidopsis plants
Pyott, D. E., Sheehan, E., & Molnar, A. (2016) · Molecular Plant Pathology · doi:10.1111/mpp.12417 · Cited by 413
Invasiveness, biology, ecology, and management of the fall armyworm, Spodoptera frugiperda
Kenis, M., Benelli, G., Biondi, A., Calatayud, P.-A., Day, R., Desneux, N., Harrison, R. D., Kriticos, D., Rwomushana, I., van den Berg, J., et al. (2023) · Entomologia Generalis · doi:10.1127/entomologia/2022/1659 · Cited by 390
Augmenting CRISPR applications in Drosophila with tRNA-flanked sgRNAs
Port, F., & Bullock, S. L. (2016) · Nature Methods · doi:10.1038/nmeth.3972 · Cited by 437
Non-viral delivery systems for CRISPR/Cas9-based genome editing: challenges and opportunities
Li, L., Hu, S., & Chen, X. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.04.031 · Cited by 415
Targeted AID-mediated mutagenesis (TAM) enables efficient genomic diversification in mammalian cells
Ma, Y., Zhang, J., Yin, W., Zhang, Z., Song, Y., & Chang, X. (2016) · Nature Methods · doi:10.1038/nmeth.4027 · Cited by 418
Therapeutic approaches for cardiac regeneration and repair
Hashimoto, H., Olson, E. N., & Bassel-Duby, R. (2018) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0036-6 · Cited by 415
The crystal structure of Cpf1 in complex with CRISPR RNA
Dong, D., Ren, K., Qiu, X., Zheng, J., Guo, M., Guan, X., Liu, H., Li, N., Zhang, B., Yang, D., et al. (2016) · Nature · doi:10.1038/nature17944 · Cited by 430
GTEx Consortium, Gamazon, E. R., Segrè, A. V., van de Bunt, M., Wen, X., Xi, H. S., Hormozdiari, F., Ongen, H., Konkashbaev, A., Derks, E. M., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0154-4 · Cited by 412
Metadata
- Authors
- Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E.
- Affiliations
- Howard Hughes Medical Institute (HHMI), University of California, Berkeley, CA 94720, USA.
- University of Vienna (AT)
- Umeå Centre for Microbial Research (SE)
- University of California, Berkeley (US)
- Howard Hughes Medical Institute (US)
- Corresponding author
- Chylinski, Krzysztof
- Doudna, Jennifer A.
- Charpentier, Emmanuelle
- Venue
- Science
- Published
- 2012-08-17
- Volume
- 337
- Issue
- 6096
- Pages
- 816-821
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC6286148
- OpenAlex
- W2045435533
- Semantic Scholar
- 68d962effe5520777791bd6ec8ffa4b963ba4f38
- Cited by
- 17,116
- References
- 48
- Citations by year
- 2026: 1083 · 2025: 1512 · 2024: 1602 · 2023: 1572 · 2022: 1795 · 2021: 1793 · 2020: 1577 · 2019: 1344 · 2018: 1255 · 2017: 1141 · 2016: 1018 · 2015: 680 · 2014: 467 · 2013: 231 · 2012: 29
- FWCI
- 180.75
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA regulation and disease
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Bacterial Genetics and Biotechnology
- Keywords
- CRISPR/Cas9, sequence-specific DNA cleavage, DNA double-strand breaks
- MeSH terms
- Bacteriophages, Base Sequence, Molecular Sequence Data, Nucleic Acid Conformation, Plasmids, RNA, Streptococcus pyogenes, Deoxyribonucleases, Type II Site-Specific, DNA Cleavage, DNA Breaks, Double-Stranded, Inverted Repeat Sequences
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.